Prognostic value of insulin-like growth factor-1 receptors in patients with colon/rectal cancer: Correlation with plasma prolactin

1995 ◽  
Vol 21 (1) ◽  
pp. 23-26 ◽  
Author(s):  
J.M. Bhatavdekar ◽  
D.D. Patel ◽  
N.G. Shah ◽  
N.H. Karelia ◽  
H.H. Vora ◽  
...  
Keyword(s):  
Rectal Cancer ◽  
Growth Factor ◽  
Prognostic Value ◽  
Plasma Prolactin ◽  
Insulin Like Growth Factor ◽  
Colon Rectal Cancer

The rôles of photoperiod and nutrition in the seasonal increases in growth and insulin-like growth factor-1 secretion in male red deer

2001 ◽  
Vol 73 (2) ◽  
pp. 305-311 ◽  
Author(s):  
J. R. Webster ◽  
I. D. Corson ◽  
R. P. Littlejohn ◽  
S. K. Martin ◽  
J. M. Suttie
Keyword(s):  
Growth Factor ◽  
Food Intake ◽  
Growth Rates ◽  
Energy Demand ◽  
Red Deer ◽  
Young Male ◽  
Live Weight ◽  
Metabolizable Energy ◽  
Plasma Prolactin ◽  
Insulin Like Growth Factor

AbstractYoung male red deer follow a seasonal growth pattern that can be shifted by altering the photoperiod they experience. An increase in photoperiod to 16 h of light per day (16L : 8D) during winter advances the onset of rapid growth and high food intake that normally commences in spring. These changes are associated with increased growth hormone (GH) and insulin-like growth factor-1 (IGF-1) secretion. The GH/IGF-1 axis is acutely sensitive to the level of nutrition and the relative rôles of photoperiod and nutrition in determining the spring IGF-1 rise is unknown. The present experiment set out to examine this by exposing two groups of deer (no. = 8 per group) to a photoperiod shift during their 1st year of life (16L : 8D from 2 June), designed to cause accelerated growth and increased food intake after approximately 7 weeks. However, after 6 weeks the food intake (pellets containing 11 MJ metabolizable energy and 160 g crude protein per kg dry matter (DM)) of one group (LDRES) was clamped, thereby preventing the intake component of the response. The intake of the other group (LDAL) remained ad libitum for a further 12 weeks until 6 October, when the experiment concluded.During the first 6 weeks of 16L : 8D, growth rate (118 (s.e. 15·4) g/day) and food intake (1·37 (s.e. 0·031) kg DM per head per day) did not differ between the groups. Food intake following the clamp in LDRES averaged 1·40 (s.e. 0·015) kg per head per day. The intake of LDAL increased 2 weeks after the clamp and thereafter was higher than LDRES (P < 0·001). Food intake of LDAL averaged 2·13 (s.e. 0·051) kg during the nutritional clamp period. Growth rates increased in both groups during the first 3 weeks of the clamp, averaging 237 (s.e. 25·0) g/day, then growth slowed in LDRES and live weights diverged. Growth rates until the end of the experiment (147 (s.e.23·0) g/ day v. 299 (s.e. 12·5) g/day, P < 0·001) and mean live weight over the last 5 weeks of the experiment were lower (P < 0·05) in LDRES than LDAL, weights reaching 88·3 (s.e. 1·86) kg and 97·9 (s.e. 2·74) kg respectively on the final sampling date. Metatarsal bone length grew more in LDAL than in LDRES (3·1 v. 2·2 cm, s.e.d. = 0·23, P < 0·01). Prior to the nutritional clamp, mean plasma prolactin and IGF-1 concentrations increased at 3 and 6 weeks after 16L : 8D respectively, in both groups. Prolactin concentrations were lower in LDRES than LDAL on two occasions, at weeks 3 and 7 after the onset of the nutritional clamp, and IGF-1 concentrations were lower in LDRES than LDAL (676 v. 872 ng/ml, s.e.d. = 73·8, P < 0·05) over the last 7 weeks of sampling.In summary, a photoperiodically driven increase in IGF-1 occurred even when the usual associated increase in food intake was prevented. This indicates that the seasonal IGF-1 rise in red deer is not a consequence of the increased food intake, although the latter appears necessary to maintain elevated IGF-1 concentrations. The rise in IGF-1 may therefore be considered as a component of the photoperiodically entrained seasonal drive to grow, and the increase in food intake a response to satisfy the increased energy demand.

scholarly journals Prognostic value of insulin-like growth factor 1 and insulin-like growth factor binding protein 3 blood levels in breast cancer

The Breast ◽  
2013 ◽  
Vol 22 (6) ◽  
pp. 1155-1160 ◽  
Author(s):  
H. Hartog ◽  
H.M. Boezen ◽  
M.M. de Jong ◽  
M. Schaapveld ◽  
J. Wesseling ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Growth Factor ◽  
Prognostic Value ◽  
Binding Protein ◽  
Blood Levels ◽  
Insulin Like Growth Factor ◽  
Factor Binding

The Impact of Ethinyl Estradiol on Metformin Action on Prolactin Levels in Women with Hyperprolactinemia

2019 ◽  
Vol 129 (01) ◽  
pp. 22-28
Author(s):  
Robert Krysiak ◽  
Witold Szkróbka ◽  
Bogusław Okopień
Keyword(s):  
Oral Contraceptive ◽  
Insulin Sensitivity ◽  
Growth Factor ◽  
Adrenocorticotropic Hormone ◽  
Hormonal Contraception ◽  
Plasma Prolactin ◽  
Insulin Like Growth Factor ◽  
Oral Contraceptive Pills ◽  
Contraceptive Pills ◽  
The Impact

Abstract Background Metformin reduced prolactin levels only in women with hyperprolactinemia. Objective The purpose of this case-control study was to compare metformin action on lactoctrope function between women receiving oral contraceptive pills and women not using hormonal contraception. Methods The study included two groups of matched women with elevated prolactin levels and new-onset prediabetes or diabetes. The first group consisted of 20 women using oral contraceptive pills for at least 12 months before entering the study, while the second group included 20 patients not using any hormonal contraception. Over the whole study period, all women were treated with metformin (1.7–3 g daily). Circulating levels of glucose, insulin, prolactin, thyrotropin, free thyroid hormones, adrenocorticotropic hormone, gonadotropins and insulin-like growth factor-1 were measured at the beginning and at the end of the study (16 weeks later). Results Thirty-eight patients completed the study. Metformin reduced plasma glucose levels and improved insulin sensitivity but the latter effect was stronger in women receiving oral contraceptive pills than in women not using any contraception. Although metformin treatment decreased plasma prolactin levels in both study groups, this effect was stronger in women taking oral contraceptive pills. Only in this group of women, metformin increased plasma luteinizing hormone levels. The changes in plasma prolactin correlated with their baseline insulin sensitivity and the effect of metformin on insulin sensitivity. Metformin did not affect plasma levels of thyrotropin, free thyroxine, free triiodothyronine, follicle-stimulating hormone, adrenocorticotropic hormone and insulin-like growth factor-1. Conclusions The obtained results suggest that the effect of metformin on overactive lactotropes depends on estrogen levels.

Seasonal patterns of growth, voluntary food intake and plasma concentrations of prolactin, insulin-like growth factor-1, LH and gonadal steroids in male and female pre-pubertal red deer (Cervus elaphus) reared in either natural photoperiod or constant daylength

1996 ◽  
Vol 62 (3) ◽  
pp. 605-613 ◽  
Author(s):  
C. L. Adam ◽  
C. E. Kyle ◽  
P. Young
Keyword(s):  
Growth Factor ◽  
Food Intake ◽  
Red Deer ◽  
Plasma Testosterone ◽  
Plasma Prolactin ◽  
Insulin Like Growth Factor ◽  
Male And Female ◽  
Natural Photoperiod ◽  
Lh Secretion ◽  
Voluntary Food Intake

AbstractRed deer calves were reared from birth to 16 months in either constant intermediate 12L: 12D daylength (ID) or in natural photoperiod (NP) (four males and four females per group) to investigate effects on the somatotropic and reproductive axes, and to compare responses between the seres. Measurements, starting from 3 months (September), were made each week of live weight (LW), voluntary food intake (VFI), plasma prolactin, plasma insulin-like growth factor-1 (IGF-1), and plasma progesterone (females), and every 2 months of pulsatile LH secretion, plasma testosterone (males), responses to exogenous GnRH, and antler development (males).Both sexes in ID compared with NP had significantly higher LW gain (males, P < 0·001; females, P < 0·01) and VFI (P < 0·001) between winter solstice (WS) and spring equinox (SE), and VFI between SE and summer solstice (SS) (males, P < 0·05; females P < 0·01). Both sexes had significantly lower plasma prolactin concentrations in ID than in NP (males, P < 0·05; females, P < 0·01) between SE and SS. However, plasma IGF-1 was only significantly altered in males, being significantly higher in ID than NP between WS and SE (P<0·01). ID and NP females showed no significant differences in pulsatile LH secretion nor in the timing of pubertal ovulation. However, ID compared with NP males at 10 months (just after SE) had higher LH and testosterone pulse frequencies (P < 0·01), and at 12 months (just before SS) had higher mean testosterone concentrations (P < 0·01) and testosterone response to GnRH challenge (P<0·001). ID antlers hardened earlier at 11 months than NP antlers at 14 months (P < 0·001).Thus ID compared with NP in both sexes prevented the winter reduction in growth and appetite and the summer elevation in prolactin secretion, and in males, but not in females, stimulated higher IGF-1 secretion in winter, an earlier increase in LH pulse frequency, and an earlier increase in gonadal steroid production. This study has therefore revealed some intriguing similarities and contrasts in the responses to photoperiod shown by young male and female deer.

Treatment related changes of the serum epidermal growth factor receptor in advanced colorectal cancer

2009 ◽  
Vol 27 (15_suppl) ◽  
pp. e22096-e22096
Author(s):  
K. G. Spindler ◽  
D. Olsen ◽  
I. Brandslund ◽  
A. Jakobsen
Keyword(s):  
Colorectal Cancer ◽  
Rectal Cancer ◽  
Epidermal Growth Factor Receptor ◽  
Growth Factor ◽  
Prognostic Value ◽  
Locally Advanced ◽  
Growth Factor Receptor ◽  
Skin Toxicity ◽  
Epidermal Growth ◽  
Pre Treatment

e22096 Background: The epidermal growth factor receptor (EGFR) is an established target for therapy in colorectal cancer. The extracellular domain of the receptor is shed into circulation and detectable by ELISA. We investigated the changes in sEGFR levels during preoperative chemoradiation (CRT) in rectal cancer patients and third-line treatment with cetuximab and irinotecan (CETIRI) in advanced disease, to elucidate the predictive or prognostic value in these settings. Methods: We included 126 healthy controls and 118 patients with chemorefractory mCRC treated with cetuximab (initial 400/m2 mg followed by weekly 250mg/m2) and irinotecan (350 mg/m2 q3w). Response was evaluated according to RECIST. Furthermore, 114 patients with locally advanced rectal tumours were treated with CRT (60 Gy/30 fractions and concomitant uftoral (300 mg/m2)/leukovorin (22.5 mg) on treatment days, followed by surgery 8 weeks post-treatment and pathological tumour regression evaluation. Pre-treatment and consecutive samples were drawn at each visit. sEGFR was measured by ELISA. Median statistics and Kaplain-Mayer curves with log-rank testing for comparison of survival rates were performed. Results: There were significant differences between the median pre-treatment sEGFR levels in controls, rectal cancer and mCRC (58 ng/ml(56–59 95% C-I), 53 ng/ml(51–55 95% C-I) and 51 ng/ml(49–53 95% C-I), respectively, p<0.000). We detected a rapid increase in sEGFR by the first on- treatment values during CETIRI (p<0.001), and a correlation between the magnitude of increase and a higher degree of skin toxicity, a well known indicator of clinical benefit to EGFR inhibitors. sEGFR in rectal cancer patients displayed a decreasing tendency during CRT (p<0.001), but no correlation to local tumour response. Patients with baseline pre-treatment level > 43.4 ng/ml (mean sEGFR of control group-2xSD) had a significantly higher OS rate than patients with low baseline levels (93% and 59% respectively, HR 0.15, P=0.002). Conclusions: We report a rapid increase in sEGFR by the onset of CETIRI, which may indicate development of skin toxicity and thereby a better change of response. Furthermore, we suggest a potential prognostic value of sEGFR measurement during CRT in locally advanced rectal cancer. No significant financial relationships to disclose.

Prognostic value of insulin-like growth factor II mRNA binding protein 3 in patients treated with radical prostatectomy

2011 ◽  
Vol 110 (1) ◽  
pp. 63-68 ◽  
Author(s):  
Thomas F. Chromecki ◽  
Eugene K. Cha ◽  
Karl Pummer ◽  
Douglas S. Scherr ◽  
Ashutosh K. Tewari ◽  
...  
Keyword(s):  
Growth Factor ◽  
Radical Prostatectomy ◽  
Prognostic Value ◽  
Binding Protein ◽  
Insulin Like Growth Factor ◽  
Factor Ii ◽  
Mrna Binding Protein ◽  
Mrna Binding
Sign in / Sign up

Export Citation Format

Share Document